When you look at JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQJAZZ)—it offers a great deal for the fundamentals it presents.

Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQJAZZ)—it offers a great deal for the fundamentals it presents.

The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, revealed by Jazz Pharmaceuticals plc (NASDAQJAZZ). New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was acquired by Jazz Pharmaceuticals in 2021.

Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile.

JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ): good value for what you're paying.

For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ) is a compelling option with its solid fundamentals.

Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.

CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.

Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5!

JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ) is an undervalued gem with solid fundamentals.

Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a U.S. marketing application in 2025.

JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ) is an undervalued gem with solid fundamentals.

Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them.

JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ) is an undervalued gem with solid fundamentals.

Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and claim the company raised Xyrem's price by over 800%.

Don't overlook JAZZ PHARMACEUTICALS PLC (NASDAQJAZZ)—it's a hidden gem with strong fundamentals and an attractive price tag.

Although cannabis stocks have been brutalized earlier, favorable legal winds could make the sector intriguing again.